sar425899 sanofi dual glp-1 glucagon agonist agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity - Winther - 2024 - Diabetes, Obesity and Metabolism Frontiers | Striking the Balance:

(2011) The effect of gastric inhibitory polypeptide on intestinal glucose absorption and intestinal motility in mice

But in humans it can be used to suppress our pain pathway

Zepbound is the only one that's FDA-approved for sleep apnea, specifically among people with obesity (defined as a BMI of over 30)

doi: 10.1093/eurheartj/ehz486 6 American Diabetes A

During this window, GLP-1 helps your body use the sugar youve just consumed and limits potentially harmful glucose spikes

Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A systematic review and network meta-analysis